当前位置: X-MOL 学术Int. Urol. Nephrol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease.
International Urology and Nephrology ( IF 2 ) Pub Date : 2020-05-26 , DOI: 10.1007/s11255-020-02509-8
Hongyu Zhang 1 , Wenqi Hu 1 , Guang Zhang 1
Affiliation  

Purpose

Asprosin was a newly identified secreted hormone which could induce hepatic glucose release. Since asprosin closely associated with the risk factors of diabetic kidney disease (DKD), including hyperglycemia, insulin resistance and inflammation, the present study aimed to investigate the relationship between circulating asprosin levels and the early stage of DKD.

Methods

30 subjects with normal glucose tolerance (NGT), 42 type 2 diabetes (T2DM) patients without DKD and 33 T2DM patients with early stage of DKD were recruited. Early stage of DKD was defined as two consecutive measurements of urinary albumin-to-creatinine ratio (UACR) 30–299 mg/g and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2. Multiple linear regression analysis was conducted to explore the associations of circulating asprosin levels with eGFR and UACR. Multiple logistic regression analysis was used to determine the association of circulating asprosin levels with the early stage of DKD.

Results

Circulating asprosin levels in Non-DKD and DKD groups were significantly higher than that in NGT group and the DKD group showed the highest levels. Circulating asprosin levels negatively correlated with eGFR (r = − 0.311, P = 0.007) and positively correlated with UACR (r = 0.345, P = 0.002) in T2DM patients. Even after multivariable adjustment, circulating asprosin levels were closely associated with eGFR and UACR and significantly increased ORs for early stage of DKD (OR = 3.973, P = 0.001).

Conclusion

Circulating asprosin levels were increased in T2DM and associated with the early stage of DKD. The specific role of asprosin in DKD needs further investigation.



中文翻译:

2型糖尿病患者中与早期糖尿病肾病相关的循环中prosprosin水平升高。

目的

Asprosin是一种新发现的分泌激素,可诱导肝葡萄糖释放。由于Asprosin与糖尿病肾病(DKD)的危险因素密切相关,包括高血糖,胰岛素抵抗和炎症,因此本研究旨在研究循环Asprosin水平与DKD早期之间的关系。

方法

招募了30名糖耐量正常(NGT),42名无DKD的2型糖尿病(T2DM)患者和33名早期DKD的T2DM患者。DKD的早期定义为连续两次测量尿白蛋白与肌酐的比率(UACR)30–299 mg / g和估计的肾小球滤过率(eGFR)≥60 mL / min / 1.73m 2。进行了多元线性回归分析以探讨循环中的prosprosin水平与eGFR和UACR的关系。多元logistic回归分析用于确定循环中的prosprosin水平与DKD早期的关联。

结果

非DKD和DKD组的循环中prosprosin水平显着高于NGT组,而DKD组显示最高水平。 在T2DM患者中 ,循环中的asprosin水平与eGFR呈负相关(r  = − 0.311,P  = 0.007),与UACR呈正相关(r = 0.345,P = 0.002)。即使经过多变量调整,循环中的prosprosin水平也与eGFR和UACR密切相关,并且在DKD的早期阶段OR显着增加(OR = 3.973,P  = 0.001)。

结论

在T2DM中,循环中的asprosin水平升高,并且与DKD的早期阶段有关。Asprosin在DKD中的具体作用有待进一步研究。

更新日期:2020-05-26
down
wechat
bug